Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Breast Cancer Res Treat. 2020 Jun 19;182(3):665–677. doi: 10.1007/s10549-020-05714-2

Fig. 5-. Plasma DNA reflects clinically occult and evident tumors in Patient #9A.

Fig. 5-

A) DNA from plasma acquired 3 months before death, buffy coat, and samples from 7 tumors acquired post-mortem from Patient #9 was used for DNA sequencing as in Fig. 1. Tumor sites sampled for DNA sequencing are indicated by green boxes. Additional tumor sites noted at autopsy (but not sampled) are indicated by black boxes. B) Mutant AFs were plotted according to organ site of tumor. For organ sites with multiple tumors, data were pooled. Data were analyzed by linear regression. C-D) Mutant AFs in plasma were compared to tumor size (mean from each organ site) determined from CT scans (C) and relative blood perfusion (mL/min) of tumor-containing organs (D) using Spearman correlation and linear regression analyses.